Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Saved in:
Bibliographic Details
Title: Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
Authors: Zhu HD; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China., Fan WJ; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, China., Zhao C; Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China., Wang S; Department of Interventional Radiology, Affiliated Hospital of Qingdao University, Qingdao, China., Li YL; Department of Intervention Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China., Jin ZC; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China., Zhang ZW; Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China., Guo JH; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China., Cheng HT; Department of Minimally Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China., Zhang Q; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China., Lu J; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China., Zeng YY; Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, China., Lv WF; Department of Interventional Radiology, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China., Xu H; Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Shao HB; Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang, China., Xu WG; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China., Zhao XY; Department of Interventional Radiology, Guizhou Cancer Hospital, Guiyang, China., Gu SZ; Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China., Lin HL; Department of Interventional Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China., Zheng WH; Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China., Piao LZ; Department of Oncology, The Affiliated Hospital of Yanbian University, Yanji, China., Song YS; Department of Interventional Radiology, Ganzhou People's Hospital, Ganzhou, China., Zhao JB; Interventional Department, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou, China., Wang YC; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China.; Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China., Hou ZG; Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Sun Y; Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Guan N; Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Huang M; Department of Minimally Invasive Interventional Therapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China., Yang WZ; Department of Interventional Radiology, Union Hospital of Fujian Medical University, Fuzhou, China., Ji JS; Department of Radiology, Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, School of Medicine, Lishui Hospital of Zhejiang University, Lishui, China., Teng GJ; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China.; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China.; State Key Laboratory of Digital Medical Engineering, Southeast University, Nanjing, China.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Apr 10; Vol. 44 (11), pp. 959-969. Date of Electronic Publication: 2026 Feb 24.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO-25-01796